Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Bicycle pedals on

    Bicycle to use £20M to move two bicycle-drug conjugates into clinic for cancer

    Ebb & Flow Bicycle pedals on Bicycle Therapeutics Ltd. plans to use a new cash injection to develop its pipeline of bicycle-drug conjugates (BDCs), with the goal of having its first candidate in the clinic for solid…

    Published on 10/20/2014
  • Figure: Money Raised in 2014

    Sticking with big Money Raised in 2014 Last week, the biotech industry raised $710 million, bringing to $42.7 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14.4 …

    Published on 10/20/2014
  • Table: Earnings on deck

    Sticking with big Earnings on deck At least 13 biotechs and pharmas are slated to report earnings this week. Two large-cap biotechs - Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Biogen Idec Inc. (NASDAQ:BIIB) - …

    Published on 10/20/2014
  • Table: EPS watch

    Sticking with big EPS watch At least three companies reported earnings last week. Shares of Baxter International Inc. (NYSE:BAX) and Johnson & Johnson (NYSE:JNJ) were off more than 2% despite beating consensus EPS …

    Published on 10/20/2014
  • Raising for Raze

    How Atlas built Raze to explore novel mitochondrial metabolism targets in cancer

    Ebb & Flow Raising for Raze Atlas Venture built platform company Raze Therapeutics Inc. to explore multiple targets and pathways associated with mitochondrial one-carbon metabolism, which the company thinks will …

    Published on 10/20/2014
  • Sticking with big

    Why Canaan is sticking with hybrid venture model for $675M tenth fund

    Ebb & Flow Sticking with big Figure: Money Raised in 2014 Table: Earnings on deck Table: EPS watch At a time when many venture firms have been raising smaller funds, Canaan Partners closed its tenth at $675 …

    Published on 10/20/2014
  • Figure: Money Raised in 2014

    Venture's banner year Money Raised in 2014 Last week, the biotech industry raised $338 million, bringing to $41.9 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14.4 …

    Published on 10/13/2014
  • Table: Earnings on Deck

    Venture's banner year Earnings on deck Earnings season kicks off this week with at least three companies slated to report financial results. 3Q14 EPS for Baxter International Inc. (NYSE:BAX) is expected to jump 10% …

    Published on 10/13/2014
  • Reloading frenzy in Europe

    Four EU VCs raise nearly $450 million in fresh cash for private biotechs

    Ebb & Flow Reloading frenzy in Europe The past two weeks have seen four European VCs raise about $450 million in either the first or final close of new funds. The flurry brings to at least $1.5 billion the amount of…

    Published on 10/13/2014
  • Sovereign data

    Kuwait Investment Authority tops up NantHealth series B with additional $250M

    Ebb & Flow Sovereign data Now that investors have injected almost half a billion dollars into NantHealth, one question is whether the subsidiary of NantWorks LLC can ever reach a valuation that justifies its war …

    Published on 10/13/2014
  • Venture's banner year

    Private biotechs poised to surpass all-time highs in venture capital raised

    Ebb & Flow Venture's banner year Figure: Money Raised in 2014 Table: Earnings on deck While the public markets have received most of the attention this year, private biotechs are poised to raise more venture …

    Published on 10/13/2014
  • 4Q14 Financial Markets Preview: 'Perfect world' - for now

    4Q biotech stocks: Large cap recovery points to smaller cap cherry picking

    With the recovery of biotech indices driven by large caps, investors are looking to cherry-pick small- and mid-caps to pad returns in 4Q.

    Published on 10/6/2014
  • 4Q14 Financial Markets Preview: Commercial race in HCV

    4Q14 investor themes: pricing in HCV race, next steps in immunotherapy, HBV

    In 4Q14, investors will focus on pricing in the HCV race, progress in cancer immunotherapy and the potential in HBV.

    Published on 10/6/2014
  • Box: Teed up for exits

    Atlas' next chapter Teed up for exits At least three of the 28 companies in Atlas Venture's active portfolio have deals under which a program or the entire company could be acquired: Annovation Biopharma Inc., …

    Published on 10/6/2014
  • Box: This way out

    Atlas' next chapter This way out Atlas Venture's five M&A exits in the past three years include Novartis AG's February acquisition of preclinical cancer immunotherapy play CoStim Pharmaceuticals Inc. and the 2012 …

    Published on 10/6/2014
  • Table: 4Q milestones

    Commercial race in HCV 4Q milestones Selected products with Phase III or regulatory milestones expected in 4Q14. (A) Uses antisense chemistry from Isis Pharmaceuticals Inc. (NASDAQ:ISIS); Source: BCIQ: BioCentury …

    Published on 10/6/2014
  • Figure: Money Raised in 2014

    Winner takes Alios Money Raised in 2014 Last week, the biotech industry raised $1.1 billion, bringing to $41.3 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14.4 …

    Published on 10/6/2014
  • Figure: London vs Europe

    Going big again London vs Europe The BioCentury Europe and BioCentury London indices both were up 5-6% in 3Q14. The largest stock in the continental European benchmark, UCB Group (Euronext:UCB), helped drive the …

    Published on 10/6/2014
  • Figure: Price-to-earnings: BT vs RX

    Going big again Price-to-earnings: BT vs RX The average P/Es for biotech and big pharma continue to converge, with biotech's multiple at about 1.3x big pharma's at the end of 3Q14 compared to 1.7x a year ago. The …

    Published on 10/6/2014
  • Figure: Results by market cap

    Going big again Results by market cap Large-cap biotechs - companies valued above $5 billion - outperformed all other market cap segments in 3Q14, led by 30%-plus gains by Sigma-Aldrich Corp. (NASDAQ:SIAL) and …

    Published on 10/6/2014
  • Table: 3Q approvals

    Going big again 3Q approvals Selected third quarter approvals. Company Approval Alimera Sciences Inc. (NASDAQ:ALIM)/pSivida Corp. (NASDAQ:PSDV; ASX:PVA) FDA approves Iluvien fluocinolone acetonide intravitreal …

    Published on 10/6/2014
  • Table: Index performance

    Going big again Index performance Index 3Q14 YTD NYSE Arca Biotechnology 11% 33% BioCentury 100 10% 23% NASDAQ Biotechnology 6% 21% BioCentury Europe 6% 24% BioCentury London 5% 12% NASDAQ …

    Published on 10/6/2014
  • Table: Restructuring watch

    Going big again Restructuring watch At least eight companies reduced their workforces during the third quarter, compared with at least 10 in the same period last year. All cash and operating loss figures in $M; …

    Published on 10/6/2014
  • Winner takes Alios

    How J&J beat out strategics in bidding for antiviral play Alios

    Ebb & Flow Winner takes Alios Figure: Money Raised in 2014 Antiviral developer Alios BioPharma Inc. raised strategic investments from three pharmas, but they all lost out to Johnson & Johnson (NYSE:JNJ). With a $1.…

    Published on 10/6/2014
  • Kadmon maneuvers

    Kadmon IPO would mix multiple technology platforms with Waksal reputations

    Ebb & Flow Kadmon maneuvers Now that Kadmon Corp. LLC has subtly signaled its interest in the public markets, the key question is whether public investors think the roles of the Waksal brothers in Kadmon add or …

    Published on 10/6/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993